Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin as symptomatic therapy of cerebellar ataxia in degenerative and inflammatory CNS-disease
DRKS00000269Phase 4Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Late-onset cerebellar ataxia (LOCA), Neurodegenerative disorders (NDDs) and multiple sclerosis (MS) comparing Gabapentin with Placebo (2 arms). Started Apr 2010; status: recruiting.
02
Drugs
gabapentin
03
Conditions
Late-onset cerebellar ataxia (LOCA)Neurodegenerative disorders (NDDs)multiple sclerosis (MS)
Beyond the preview
Go deeper on DRKS00000269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000269.